Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$132.76 +1.5%	$130.44	$99.71 ▼ $141.23	$230.25B	0.7	5.85 million shs	9.67 million shs
AZN AstraZeneca	$73.50 -0.4%	$73.69	$62.75 ▼ $87.68	$227.94B	0.41	5.09 million shs	3.89 million shs
PFE Pfizer	$25.36 +0.6%	$26.05	$24.48 ▼ $31.54	$143.80B	0.61	38.94 million shs	53.46 million shs
SNY Sanofi	$55.46 -0.6%	$55.22	$45.22 ▼ $60.12	$140.75B	0.58	2.26 million shs	1.56 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+1.49%	+4.29%	-3.79%	+17.38%	+16.81%
AZN AstraZeneca	-0.39%	-0.80%	-3.56%	+12.18%	+8.49%
PFE Pfizer	+0.61%	-2.98%	-4.07%	-4.43%	-8.63%
SNY Sanofi	-0.64%	-0.84%	+1.82%	+14.99%	+14.12%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.9025 of 5 stars	2.4	4.0	4.2	4.5	3.5	2.5	2.5
AZN AstraZeneca	2.826 of 5 stars	2.6	5.0	1.7	0.0	3.0	0.0	1.3
PFE Pfizer	4.9802 of 5 stars	3.3	3.0	4.2	4.2	2.7	3.3	3.1
SNY Sanofi	3.5073 of 5 stars	2.5	3.0	2.5	0.0	3.3	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.84	Moderate Buy	$137.94	3.90% Upside
AZN AstraZeneca	3.10	Buy	$89.75	22.11% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	25.90% Upside
SNY Sanofi	3.00	Buy	$62.50	12.69% Upside

Current Analyst Ratings Breakdown

Latest AZN, ABT, PFE, and SNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	SNY Sanofi	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	ABT Abbott Laboratories	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$133.00 ➝ $150.00
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/4/2025	ABT Abbott Laboratories	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$135.00 ➝ $160.00
3/4/2025	ABT Abbott Laboratories	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$138.00 ➝ $154.00
2/13/2025	AZN AstraZeneca	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy
2/12/2025	AZN AstraZeneca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
2/10/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
1/30/2025	SNY Sanofi	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.49	$5.72 per share	23.22	$22.36 per share	5.94
AZN AstraZeneca	$54.07B	4.22	$6.23 per share	11.79	$13.18 per share	5.58
PFE Pfizer	$63.63B	2.26	$3.97 per share	6.38	$15.81 per share	1.60
SNY Sanofi	$44.29B	3.18	$5.46 per share	10.16	$33.20 per share	1.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.65	17.35	23.17	2.52	31.95%	20.74%	11.19%	4/16/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.26	32.52	14.70	1.42	13.01%	32.23%	12.31%	4/24/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.98	8.37	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
SNY Sanofi	$6.02B	$2.49	22.27	11.68	1.01	12.77%	25.61%	14.72%	4/24/2025 (Estimated)

Latest AZN, ABT, PFE, and SNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	AZN AstraZeneca	$1.10	N/A	N/A	N/A	N/A	N/A
4/24/2025	N/A	SNY Sanofi	$0.87	N/A	N/A	N/A	$9.79 billion	N/A
4/16/2025	N/A	ABT Abbott Laboratories	$1.07	N/A	N/A	N/A	$10.38 billion	N/A
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/30/2025	Q4 2024	SNY Sanofi	$0.70	$0.70	N/A	$0.29	$10.57 billion	N/A
1/22/2025	Q4 2024	ABT Abbott Laboratories	$1.34	$1.34	N/A	$5.27	$11.03 billion	$10.97 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.78%	+7.17%	30.85%	54 Years
AZN AstraZeneca	$2.06	2.80%	+1.98%	91.15%	N/A
PFE Pfizer	$1.72	6.78%	+2.50%	121.99%	16 Years
SNY Sanofi	$1.47	2.65%	+1.84%	59.04%	N/A

Latest AZN, ABT, PFE, and SNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/21/2025	ABT Abbott Laboratories	quarterly	$0.59	1.75%	4/15/2025	4/15/2025	5/15/2025
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.32	1.60	1.14
AZN AstraZeneca	0.65	0.93	0.74
PFE Pfizer	0.63	1.00	0.73
SNY Sanofi	0.15	1.46	1.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
AZN AstraZeneca	20.35%
PFE Pfizer	68.36%
SNY Sanofi	14.04%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
AZN AstraZeneca	N/A
PFE Pfizer	0.06%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	115,000	1.73 billion	1.73 billion	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
SNY Sanofi	91,600	2.54 billion	2.51 billion	Optionable

AZN, ABT, PFE, and SNY Headlines

Recent News About These Companies

FDA Approves Sanofi's Hemophilia Drug

March 31 at 9:15 AM | benzinga.com

Sanofi (NASDAQ:SNY) Shares Sold by Barrow Hanley Mewhinney & Strauss LLC

March 31 at 5:56 AM | marketbeat.com

7,840 Shares in Sanofi (NASDAQ:SNY) Acquired by Congress Wealth Management LLC DE

March 31 at 4:02 AM | marketbeat.com

Sanofi Consumer Healthcare India Limited Announces Postal Ballot Results

March 30 at 3:17 AM | tipranks.com

Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing

March 29 at 4:43 AM | econotimes.com

FDA approves Sanofi treatment for hemophilia A or B

March 28, 2025 | markets.businessinsider.com

FDA Approves Sanofi's (SNY) Qfitlia for Hemophilia Treatment

March 28, 2025 | gurufocus.com

FDA approves Sanofi’s hemophilia treatment Qfitlia

March 28, 2025 | in.investing.com

Regeneron, Sanofi announce Dupixent authorization in Japan

March 28, 2025 | markets.businessinsider.com

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

March 28, 2025 | globenewswire.com

US FDA approves Sanofi's bleeding disorder therapy

March 28, 2025 | reuters.com

Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment

March 28, 2025 | tipranks.com

LPL Financial LLC Buys 142,290 Shares of Sanofi (NASDAQ:SNY)

March 28, 2025 | marketbeat.com

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

March 28, 2025 | globenewswire.com

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag

March 26, 2025 | zacks.com

Sanofi’s Tolebrutinib and Chlamydia Vaccine Achieve Regulatory Milestones

March 26, 2025 | tipranks.com

Zions Bancorporation N.A. Raises Stock Holdings in Sanofi (NASDAQ:SNY)

March 26, 2025 | marketbeat.com

Sei Investments Co. Raises Holdings in Sanofi (NASDAQ:SNY)

March 26, 2025 | marketbeat.com

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

March 26, 2025 | zacks.com

Sanofi (NASDAQ:SNY) Receives Average Rating of "Buy" from Brokerages

March 26, 2025 | americanbankingnews.com

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN, ABT, PFE, and SNY Company Descriptions

Abbott Laboratories NYSE:ABT

$132.76 +1.94 (+1.49%)

Closing price 03/31/2025 03:59 PM Eastern

Extended Trading

$132.10 -0.66 (-0.50%)

As of 03/31/2025 07:51 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$73.50 -0.29 (-0.39%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$72.75 -0.75 (-1.02%)

As of 03/31/2025 07:11 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Pfizer NYSE:PFE

$25.36 +0.15 (+0.58%)

Closing price 03/31/2025 03:59 PM Eastern

Extended Trading

$25.29 -0.07 (-0.26%)

As of 03/31/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sanofi NASDAQ:SNY

$55.46 -0.36 (-0.64%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$55.30 -0.16 (-0.29%)

As of 03/31/2025 06:37 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time